Aftermarket
Check out the latest Health news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts.
Health & Biotech
Scott Power: Cardiac pacing device developer EBR hits Morgans price target amid ‘rotation back into healthcare’
Health & Biotech
Cardiex launches app, begins US Deliveries of flagship CONNEQT Pulse
Health & Biotech
Health Check: From feather duster to rooster, Nanosonics again rules the roost
Health & Biotech
LTR Pharma inks national pharmacy distribution deal for its ED therapy
Health & Biotech
Orthocell soars 14% after crushing early sales growth for Remplir
Health & Biotech
Island completes phase 2b enrolments in dengue fever trial
Health & Biotech
Biocurious: EZZ’s tennis sponsorship serves up 300 million Chinese viewers
Health & Biotech
Health tech Thrive Tribe serves up a new star chief exec
Health & Biotech
Recce Pharmaceuticals doses all patients in phase II skin infection trial
Health & Biotech
Health Check: Did the earth move for you? The world shifts on its axis as it enters the Trump era mark two
Health & Biotech
Dr Boreham’s Crucible: Radiopharm hopes to turn up the sweet sound of success
Health & Biotech
EBR’s US heart lead hopes tick up after wireless device gets nod for fast-track reimbursement pathway
Health & Biotech
Health Check: Investor hearts pump as EBR girds for US approval of novel pacemaker leads
Stockhead TV
Road to 2025: Clinical trials hit fever pitch for Island Pharmaceuticals
Aftermarket
9 alternatives to coffee for a natural energy boost
Stockhead TV
Road to 2025: EBR Systems gets ahead of the pacemaker pack
Health & Biotech
Singular Health Group fulfils Phase 1 of US remote medical image aggregation MOU with PNS
Health & Biotech
Scott Power: Telix achieves sustained growth; Pro Medicus wins another contract
Health & Biotech
First paediatric patient recruited for Dimerix’s ACTION3 kidney disease drug trial
Stockhead TV
Road to 2025: DXB helping to treat kidney and respiratory disease
Stockhead TV
Road to 2025: Race on track with clinical trials
Health & Biotech
Health Check: Biotech partnership eyes Euro market expansion for Rett syndrome drug
Health & Biotech
Vital Signs Podcast: Aroa Biosurgery’s difference-making diagnosis
Health & Biotech
Health Check: Mesoblast shares sink despite $260m placement and FDA win
Health & Biotech
Lumos teams with MedPro to expand US reach of FebriDx point-of-care respiratory test
Stockhead TV
Road to 2025: How Lumos has diagnosed its place in the market
Health & Biotech
Health Check: Telix to acquire next-gen therapeutics and biologics platform
Stockhead TV
Road to 2025: Control Bionics’ breakout into sports science
Health & Biotech
Scott Power: Which health stock bled this week after an earnings downgrade?
Stockhead TV
Long Shortz with Island Pharmaceuticals: Phase 2b trial into dengue fever kicks off
Stockhead TV
Road to 2025: A look into healthcare’s future
Stockhead TV
Road to 2025: Don’t blink and miss this mental healthcare company
Health & Biotech
Health Check: Which stock just dumped 19% on earnings downgrade?
Health & Biotech
Island Pharmaceuticals starts phase 2b dengue trial
Health & Biotech
Orthocell achieves third consecutive quarter of record revenue
Health & Biotech
Health Check: New JV for Opyl; Dimerix inks another licensing deal
Stockhead TV
Break it Down: Dimerix inks major Japanese partnership
Health & Biotech
Dimerix inks lucrative licensing deal for kidney drug in Japan
Stockhead TV
Road to 2025: AdAlta’s push to advance lead drug AD-214 for deadly IPF
Health & Biotech
Health Kick Podcast: Neurizon gears up for big year in tackling ALS
Health & Biotech
Aroa’s study shows Myriad’s impact in lower limb surgery
Health & Biotech
Dr Boreham’s Crucible: This cancer-tackling biotech might just have a fighting chance
Stockhead TV
Road to 2025: EZZ on a mission to advance quality of life and health
Health & Biotech
The storied Australian drug developer turning his skills to funds management
Health & Biotech
Health Check: With yet another customer win, Pro Medicus storms to 2024 finish line with a wet sail
Health & Biotech
ASX healthcare 2024 winners and losers, plus what’s next for 2025
Experts
Small cap gems set to blow the lights out in 2025 (part two)
Load More